Preclinical evaluation of [²¹¹At]At-AuNP-ABDMPL16 for targeted alpha therapy in Melanoma.

ABSTRACT:

Purpose

The aim of this study is to overcome the challenges of poor tumor penetration and systemic toxicity in targeted alpha therapy (TAT) while also evaluating its immunomodulatory effects to enhance antitumor immune responses in melanoma treatment.

Methods

This study developed a ²¹¹At-labeled single-domain antibody agent ([²¹¹At]At-AuNP-ABDMPL16) targeting PD-L1, a protein overexpressed in melanoma cells. The binding affinity and internalization of [²¹¹At]At-AuNP-ABDMPL16 were evaluated in vitro using melanoma cell lines. In vivo studies in melanoma-bearing mice were conducted to assess biodistribution, pharmacokinetics, therapeutic efficacy, and the immune response induced by the treatment.

Results

[²¹¹At]At-AuNP-ABDMPL1

SUBMITTER: Zhang J 

PROVIDER: S-EPMC12491104 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature